BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR+/HER2-...
Автор: ecancer
Загружено: 2019-06-20
Просмотров: 2465
Описание:
Prof Hope Rugo speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the BYLieve study.
She describes the aim and methodology of the study, which was to assess the efficacy and toxicity of alpelisib in combination with endocrine therapy in patients who have received prior CDK4/6 inhibitors.
Prof Rugo also discusses the results from this interim analysis, which includes reasonable response rates which was in accordance with the data achieved in the SOLAR-1 study. A much lower discontinuation rate was also achieved in this study.
She believes the use of PI3-kinase inhibitors, such as alpelisib is an exciting advancement in personalising treatments for breast cancer.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
